The UK and US have established a key trade agreement that will keep no tariffs on UK drug shipments entering the US market.
Agreement Details of the Deal
As part of the deal, the UK has committed to increase funding on pharmaceuticals through the public health system. This move ensures that tariffs on these vital goods will be held at nothing for a duration of 36 months.
This agreement follows previous statements to significantly raise duties on patented drug imports, with increases mentioned as high as one hundred percent.
"This agreement with the Britain reinforces the worldwide climate for innovative medicines and introduces long-overdue fairness to American-British drug exports," a release said.
Economic Impact
Drugs represent one of the the United Kingdom's largest exports to the America, which is by far the largest market for leading companies like GSK and AstraZeneca.
Export figures show that in the year prior to September, the UK exported pharmaceutical products totaling billions to the US. This amount represented a significant portion of total UK exports in that span.
"This deal protects jobs, increases funding and paves the way for the UK to establish itself as a global hub for life sciences," the Business and Trade Secretary remarked.
Detailed British Pledges
The deal includes several specific pledges from the UK:
- Revised Affordability Limit: The UK will increase the cost ceiling at which it considers new therapies to be too expensive by twenty-five percent.
- Higher Drug Budget: There is a goal to double total public funding on drugs from 0.3% of GDP to 0.6% over the following ten-year period.
- Refund Ceiling: The amount drug companies must refund to the NHS to prevent overspending will be capped at fifteen percent. Last year, repayments were more than twenty percent.
Industry Background
The deal follows a ongoing tension between the sector and the ministers over spending levels and regulatory access.
These tensions were intensified by arguments that US patients were charged a premium for the identical medicines than consumers in the other developed nations.
Recently, several major drug company projects in the UK have been halted or scrapped, while multi-billion-dollar investments have been pledged toward projects in the United States.
One official acknowledged that the NHS had to spend more on medicines, noting that its spending on drugs had declined as a proportion of its total funding over the previous ten-year period.
